

DOI: 10.14744/ejmi.2021.75116 EJMI 2021;5(3):347-353

**Research Article** 



# Utilization of Advanced Molecular Analyses in Clinical Practice in Lung Cancer: A Country Perspective

## Itaci Ibrahim Petekkaya,<sup>1</sup> D Veysel Atilla Ayyildiz<sup>2</sup>

<sup>1</sup>Department of Internal Diseases (Medical Oncology), Izmir Tinaztepe University, Faculty of Medicine, Izmir, Turkey <sup>2</sup>Department of Radiology, Suleyman Demirel University, Faculty of Medicine, Isparta, Turkey

#### Abstract

**Objectives:** This study evaluated the clinical practices of medical oncologists in Turkey for utilization of molecular and genetic analyses in lung cancer.

**Methods:** All medical oncologists registered to the Turkish Medical Oncology Society participated in an online survey about their practices of molecular and genetic analyses for management of lung cancer patients.

**Results:** Participants were 189 medical oncologists. Results showed that 88.4% checked mutations in adenocancer, 75.7% checked EGFR, EML-ALK, and ROS-1 in NSCLC, 75.1% checked markers only for locally advanced/metastatic diseases; 45% obtained results in 8–14 days and 31.2% in 15–21 days. A positive EGFR/ALK report after initiating chemo led 68.3% to re-evaluate patient after 2/3 cycles, 20.6% to stop chemo and shift to targeted therapy and 12.2% to continue full-regimen. Of the participants, 46% requested secondary biopsy in progressions under treatment, 22.2% in young patients, 34.9% in never-smokers, 46.6% in patients testing negative but presumed to be clinically positive.

**Conclusion:** Most medical oncologists in Turkey use molecular/genetic analyses in their clinical practice. However, the limited availability and delays in results lead oncologists to initiate treatment primarily based on clinical findings. Once these methods become widespread, targeted therapies and consequent favorable outcomes will increase in the practice of oncology.

Keywords: Molecular analyses, precision oncology, medical oncologist, perspective, Turkey

*Cite This Article:* Petekkaya HI, Ayyildiz VA. Utilization of Advanced Molecular Analyses in Clinical Practice in Lung Cancer: A Country Perspective. EJMI 2021;5(3):347–353.

Cancer is a disease that basically originates from genomic disorders, which play a role in both progression of the disease and also in escape from treatment.<sup>[1-3]</sup> In this complex environment of genetic interactions, molecular profiling analyses have emerged as a standard of care in many cancer types.<sup>[4, 5]</sup> The widespread utilization of molecular profiling analyses has brought the concept of precision oncology into today's oncology practice.

One of the most important application fields of molecular studies in oncology is lung cancer. Today, lung cancer ranks

first for men and fourth for women for mortalities due to cancer in Turkey.<sup>[6]</sup> The ongoing research for identifying molecular pathogenesis of lung cancer reveals novel molecular targets for treatment. Currently, targeted therapies for patients with epidermal growth factor receptor (EGFR) tyrosine kinase mutations and anaplastic lymphoma kinase (ALK) gene translocations provide improved outcomes in both survival and health-related quality of life.<sup>[7-10]</sup> Some of the other targets for molecular profiling are KRAS mutations, MET overexpression, and ROS1 translocations.<sup>[11-13]</sup> As

Phone: +90 232 454 14 14 E-mail: drpetekkaya@gmail.com

Submitted Date: April 01, 2021 Accepted Date: August 24, 2021 Available Online Date: September 22, 2021 <sup>®</sup>Copyright 2021 by Eurasian Journal of Medicine and Investigation - Available online at www.ejmi.org OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.



Address for correspondence: Haci Ibrahim Petekkaya, MD. Ic Hastaliklari Anabilim Dali (Medikal Onkoloji), Izmir Tinaztepe Universitesi Tip Fakultesi, Izmir, Turkey

research continues, novel biomolecules and potential targets for contemporary treatments will emerge for management of lung cancer.

The advances in the field of biotechnology cannot be separated from the practice patterns of medical oncologists for management of lung cancers. The availability of laboratories in healthcare facilities, wait times for obtaining the results of molecular analyses, patient factors and the physician choices for management of the disease are major factors that affect the demand for and application of molecular analyses. Currently, there is no baseline data regarding utilization of molecular analyses in the clinical practice of lung cancer management in Turkey. This study aimed to evaluate the daily clinical practices of medical oncologists regarding utilization of these methods in lung cancer patients in the context of a country.

# Methods

This study was conducted as a cross-sectional study to evaluate the current practice patterns of medical oncologists in Turkey for utilizing molecular analyses as a part of patient management in lung cancer. For this aim, a nineteen-item questionnaire was designed to evaluate the demographic characteristics and work environment of the participants, their knowledge about molecular and genetic analysis methods and barriers to utilization of these methods in clinical practice. The questionnaire is presented in Table 1.

The target population of this study included all medical oncologists registered in the database of the Turkish Medical Oncology Society who were called to participate to an online survey. A total of 189 medical oncologists completed the survey and were included in the analyses.

### **Statistical Analysis**

Descriptive statistics are presented as frequencies and percentages for the categorical variables and means and standard deviations for the numerical variables. Analyses were performed with SPSS 21 (IBM Inc., Armonk, NY, USA).

# Results

A total of 189 medical oncologists (M/F: 117/71; mean age:  $39.3\pm6.7$  years) participated the study. The distribution of the participants' institutions was as 48.7% university hospital (n=92), 32.8% research and training hospital (n=62), 18% private practice (n=34) and 0.5% foundation university hospital (n=1).

About 88.4% of the participants declared that they referred patients to molecular or genetic mutation analyses for adenocancers in their clinical practice. The proportion of the participants' institutions that were able to analyze molecular tests was 61.4%, and 52.9% of the participants reported that they referred patients to another center for these analyses.

About 75.7% of the participants declared that they checked for all among EGFR mutation, EML-ALK fusion and ROS-1 mutation in patients with NSCLC, and 58.2% stated that they had no priority for choosing these markers. The proportion of the participants who checked for these markers at diagnosis in locally advanced or metastatic disease was 75.1%.

Of medical oncologists that participated in the survey, 88.4% reported that these analyses were requested by themselves. Almost half of them could obtain the results in between 8 and 14 days (45%), and some in 15 to 21 days (31.2%).

In cases where chemotherapy was initiated at diagnosis but were then reported to be EGFR or ALK-positive, 68.3% of the participants reported that they should decide after 2 or 3 cycles of chemotherapy, 20.6% reported that they should cease the chemo and shift to targeted therapy, and 12.2% reported that they should continue with chemotherapy. The rate of providing maintenance regardless of mutation status in patients that responded to chemotherapy was 36%. The cytotoxic chemotherapy regimen of choice at first line in metastatic adenocancers that took targeted therapy regardless of mutation status was reported to be cisplatin+pemetrexed by 50.2% of the participants.

The mutation analyses were reported to be performed from the primary tumor mass by 95.8% of the participants, and 91.5% of them reported that they request a re-biopsy in case of inadequate material for molecular studies. The rate of re-biopsy in case of an EGFR/ALK discordance was 38.1%. The distribution of re-biopsy preference was as 46.6% for patients that tested negative but clinically positive based on the oncologist's consideration, 46% for every patient that progressed during treatment, 34.9% for patients who had not smoked before and 22.2% for young patients.

The detailed distribution of responses to the questionnaire is presented in Table 2.

### Discussion

Incorporation of molecular and genetic testing in treatment of lung cancer along with other clinical data from laboratory and imaging studies significantly affect patient outcomes and provide more favorable survival rates and quality of life in these patients. Additionally, these tests guide medical oncologists towards better patient management

1. Age:;	Male	Female
2. Your institution:	University	Education and research hospital
	Foundation university	Private practice
3. For which subtyp	es of lung cancer do you check molecular or genetic mutati	ions in your clinical practice?
	Unknown subtype	
	□ Other:	
4. Does your institu	tion have the capability to analyze molecular markers?	
·	□ Yes	□ No
	If "No":	I refer to another center
		I do not check molecular tests
. Which molecular	markers do you check in a patient with a newly diagnosed l	NSCLC?
	□ Only EGFR mutation (according to the clinical data)	
	□ Only EML-ALK fusion (according to the clinical data)	
	<ul> <li>Only ROS-1 mutation (according to the clinical data)</li> </ul>	
	□ All of the above	
	□ Other:	
Do you check mo	lecular markers based on a priority ranking?	
. Do you check mo		□ No
f"Yes":	<ul> <li>Based on reimbursement</li> </ul>	
i les.	<ul> <li>Based on rembursement</li> <li>Based on a readily available kit</li> </ul>	
7 Which mothod is	□ Based on the clinical status of the patient used for ALK mutation?	
. which method is		
	FISH	
	Immunohistochemistry and subsequent FISH	
. When do you che	ck for molecular markers?	
	□ In all NSCLCs even non-metastatic	
	□ At diagnosis of locally advanced or metastatic patients	
	□ At second line in metastatic patients	
	□ After metastasis in metastatic patients	
9. Who makes reque	ests for checking molecular or genetic mutations?	
	Myself	
	My colleague (medical oncologist)	
	$\Box$ Another colleague from other specialties:	
0. When do you re	ceive the results of molecular marker tests?	
	□ 1-7 days	
	□ 8-14 days	
	□ 15-21 days	
	More than 21 days	
1. If more than 21	days, what is the reason for this long period?	
12. What is your ap chemotherapy?	proach to a patient who took chemotherapy at diagnosis ar	nd reported to be EGFR or ALK-positive after initiation of
	I continue with chemotherapy	
	$\Box$ I cease chemotherapy and shift to targeted therapy	
	$\Box$ I decide according to assessment after 2 or 3 cycles of c	hemo
13. Do you give mai	ntenance to patients that responded to chemotherapy rega	ardless of mutation status?
	□ Yes	□ No
f"Yes":	□ After which cycle?	

#### Table 1. CONT.

15. How are the mutation analyses reimbursed?				
□ SGK (social security institution)				
Patient self-sponsored				
$\Box$ SGK and patient share				
Being included in compassionate use				
□ Other:				
16. What is the primary site for mutation analyses?				
Primary lung tumor mass				
Mediastinal LAP				
Metastasis site				
17. If there is no adequate biopsy material for molecular study, do you recommend re-biopsy?				
$\Box$ Yes $\Box$ No				
18. Do you request a second biopsy in cases of EGFR/ALK discordance?				
□ Yes □ No				
19. For which cases do you request a second biopsy?				
For every patient that progressed during treatment				
$\square$ For patients that test negative but clinically positive based on my consideration				
For young patients				
For patients who have not smoked				

and for better choice of medications that are available. The current literature data suggest that even patients with poor performance may respond well to targeted therapies, which should inform physicians about the importance of these molecular and genetic evaluations.<sup>[14, 15]</sup> Under the light of these general considerations about these methods, identification of the preferences of medical oncologists for utilizing these assessments during their clinical practice gains importance. Since there is no baseline data on this topic in Turkey, this study aimed to constitute a basic foundation of comprehension regarding the current status of preferences for molecular and genetic testing in medical oncology society in Turkey.

As an overall interpretation of our findings, the majority of our sample were familiar with molecular and genetic testing methods and used these analyses for patient management in their clinical practice. The main barriers against using these methods were the limited availability at some centers and delays in obtaining the results of these analyses. In these cases, the medical oncologists tended to initiate treatment, based on primarily clinical findings and routine laboratory and imaging studies.

Currently, the available literature data suggest several barriers for adoption of molecular and genetic testing in the practice of oncology. One of these barriers is skepticism about the clinical value of these methods in the practice. <sup>[16, 17]</sup> This skepticism is particularly about next-generation sequencing techniques that incorporate multiple gene mutation analyses rather than single gene and molecular

marker analyses. A recent survey study about the beliefs of clinicians about the clinical value and utility of these tests in clinical practice revealed that only half of the participating physicians believed that these tests will be widely available in clinical practice over several years of utilization.<sup>[16]</sup> Some factors might underlie this skepticism, like inadequate knowledge about genomics, unavailability of resources or patient-related factors. Particularly, wait time to obtain the results of molecular studies is known as a major factor that affects incorporation of these tests into clinical practice.<sup>[16]</sup> The results of our study also confirmed this finding in the literature, and almost half of our participants stated that they obtained the results of molecular analyses after 15 days or more, which is a significant barrier against widespread adoption of these methods in routine practice.

Another unfavorable issue that emerges as a barrier is the possible need for re-biopsies in molecular studies. After an initial invasive procedure, both patients and physicians become more reluctant for an additional invasive procedure to obtain more tissue samples for analyses.<sup>[18]</sup> Nevertheless, the literature data are partly in conflict with our results. Accordingly, more than 90% of our participants declared that they requested a re-biopsy in case of an inadequate tissue sample. However, if an EGFR/ALK discordance were determined, only less than 40% of them would request a re-biopsy, which indicated a reluctance against re-biopsies in molecular testing.

The participants of our study emphasized the importance of reimbursement for molecular testing as a priority-deter-

\_

For which subtypes of lung cancer do you check molecular or genetic mutations in your clinical practice?         88           Adenocancer         167         88           Squannous         5         24           Unknown subtype         93         94           Dees your institution have the capability to analyze molecular markers?         73         93           Wes         100         52           Inforce         73         93           Who not check molecular tests         100         52           I do not check molecular tests         1         00           Mich molecular markers do you check in a patient with a newly diagnosed NSCLC7         7         93           Only KEGR mutation (according to the clinical data)         -         -         -           Only KEGR mutation (according to the clinical data)         -         -         -           Only KEGST mutation (according to the clinical data)         -         -         -           Do you check molecular markers based on a priority ranking?         10         10         50           Vich molecular markers do you check in a patient         50         26         40           No         -         -         -         -         -           Out heck molecular markers do you check in a	Table 2. Participants' responses to the questionnaire																																																																																																		
Adenciancian         167         188           Squamous         5         22           Unknown subtype         93         49           All NSCLC         28         14           Dees your institution have the capability to analyze molecular markers?         116         61.           No         73         38           f*No*:         116         61.           I do not check molecular tests         10         02.           Multich molecular markers do you check in a patient with a newly diagnosed NSCLC?         1         00.           Only ESFR mutation (according to the clinical data)         -         -           Only ESFR mutation (according to the clinical data)         -         -           Only ESFR mutation (according to the clinical data)         -         -           Only ESFR mutation (according to the clinical data)         -         -           Only ESFR mutation (according to the clinical data)         -         -           Only ESFR mutation (according to the clinical data)         -         -           So ucheck molecular markers based on a priority ranking?         13         75.           Wes         76         40.         No         110         58.           Based on reality available kit         21	Items	n	%																																																																																																
Squamous52.2Unknown subtype9349.All NSCLC814.Does your institution have the capability to analyze molecular markers?166.61.No7383.73.No73100.5.2I do not check molecular tests100.5.2I do not check molecular tests100.5.2I do not check molecular tests25.13.Only KG-TK fusion (according to the clinical data)Only KG-TK fusion (according to the clinical data)Only KG-TK fusion (according to the clinical data)Only KG-T mutation (according to the clinical data)Do you check molecular markers based on a priority ranking?10.5.6Teres?:76.40.10.No110.5.67.640.No110.5.67.640.No110.5.67.640.No110.5.67.640.No110.5.67.640.No110.5.67.640.No111.5.81.640.Nich method is used for ALK mutation?1.67.6FISH111.5.31.643.Immunohistochemistry and subsequent FISH1.15.3Inmunohistochemistry and subsequent FISH1.68.Vhen do you check for molecular marker test?7.79.1111.313.53		167	00.4																																																																																																
Unknown subtype         93         49           All NSCLC         28         14           Dees your institution have the capability to analyze molecular markers?         16         61.           Yes         116         61.         73         38           I'No         3         38.         74.00         52.         13         05.           I'refer to another center         10         05.22.         14.00         05.22.         14.00         05.02.         05.																																																																																																			
All NSCLC         28         14           Does your institution have the capability to analyze molecular markers?         116         6.1           No         73         38           five 7:         110         5.2           I refer to another center         100         52           I do not check molecular markers do you check in a patient with a newly diagnosed NSCLC?         13           Only KMLAKI Kuison (according to the clinical data)         -         -           Only KKI Kuison (according to the clinical data)         -         -           Only KKI Kuison (according to the clinical data)         -         -           Only KKI Kuison (according to the clinical data)         -         -           Outheck molecular markers based on a priority ranking?         110         50           Other         21         10.0         20           No         110         53         17           Wink method is used for ALK mutation?         11         14           TFMS+         11         54         26           Based on reading valiable kit         21         11         53           Immunohistochemistry         11         54         54           I hat NSLCS even non-metastatic patients         3         15	•																																																																																																		
Does your institution have the capability to analyze molecular markers?         116         61,           Yes         116         61,           No         10         52,           Irker to another center         10         52,           Ird nort check molecular tests         1         0.0           Which molecular markers do you check in a patient with a newly diagnosed NSCLC?         13,           Only EGFR mutation (according to the clinical data)         -         -           Only MALK fusion (according to the clinical data)         -         -           Only KGT mutation (according to the clinical data)         -         -           Only KGT mutation (according to the clinical data)         -         -           Only KGT mutation (according to the clinical data)         -         -           Only KGT mutation (according to the clinical data)         -         -           Do you check molecular markers based on a priority ranking?         10         16           No         5         64         -         -           Which melotic si																																																																																																			
Yes1161661No7338.f*No*:101 refer to another center1052.1 do not check molecular markers do you check in a patient with a newly diagnosed NSCLC?100.Only EGFR mutation (according to the clinical data)Only MSO-1 mutation (according to the clinical data)Ohly GER mutation (according to the clinical data)Only MSO-1 mutation (according to the clinical data)Only MSO-1 mutation (according to the clinical data)Only MSO-1 mutation (according to the clinical data)No110SB-No110SB-More method is used for ALK mutation?FISH115.5-I mall NSUCS even non-metastatic179I nal NSUCS even non-metastatic patients31.2At diagnosis of locally advanced or metastatic patients31.2Mycolf molecular markers?I nal NSUCS even non-metastatic patients32.0Mycolf mague (medical oncologist)432.2 <t< td=""><td></td><td>20</td><td>14.0</td></t<>		20	14.0																																																																																																
No7338.f*No*:1052.I do not check molecular tests10.00Which molecular markers do you check in a patient with a newly diagnosed NSCLC?13.Only EGFR mutation (according to the clinical data)Only EGFR mutation (according to the clinical data)Only Rotation (according to the clinical data)Do you Check molecular markers based on a priority ranking?1058.On No11058f*Nes*;5026.26.Based on reimbursement5026.26.Based on reimbursement5026.26.Based on teimbursement5026.26.Immunohistochemistry and subsequent FISH1151.Immunohistochemistry and subsequent FISH311.I all NSCLCS even non-metastatic patients33.At tiggnosis of locally advanced or metastatic patients33.At tiggnosis of locally advanced or metastatic patients33.Miter metastatis in metastatic patients33.3.Miter metastatis in metastatic patients33.3.Miter metastatis in metastatic patients33.3.Miter metastatis in metastatic patients33.3.Miter metastatis in		116	61.4																																																																																																
If "No":         100         52.           I refer to another center         100         52.           I do not check molecular tests         1         0.0           Which molecular markers do you check in a patient with a newly diagnosed NSCLC?         1         0.0           Only GEM mutation (according to the clinical data)         -         -           Only MOS-1 mutation (according to the clinical data)         -         -           All of the above         143         75.           Other         21         100.0           Do you check molecular markers based on a priority ranking?         -         -           Yes         76         40.0           No         110         43.0         40.0           No         110         43.0         75.0           Mich method is used for ALK mutation?         11         13.0           FisH         11         53.0         17.0           Immunohistochemistry and subsequent FISH         30         15.0           Nhe do you check for molecular markers?         1         42.0           I all NSLCS even non-metastatic patients         38         20.0           Whe do you check for molecular marker sts?         1         43.0         21.0			38.6																																																																																																
I refer to another center10052,I do not check molecular tests10.2I do not check molecular tests10.2Ohly EGFR mutation (according to the clinical data)21Only MCM-1K (kison (according to the clinical data)Only MCM-121100Do you check molecular markers based on a priority ranking?Yes76400No11058frives?:Based on reimbursement5026Based on reimbursement5026Based on the clinical status of the patient2111Mich method is used for AK truatation?FISH115315Immunohistochemistry and subsequent FISH3015Inall NSCLCS even non-metastatic1474At diagnosis of locally advanced or metastatic patients3820Who makes requests for checking molecular marker sts?I 7 days189.231More than 21 days35-34More than 21 days32034More than 21 days32034More than 21 days32034More than 21 days33434More than 21 days	If "No":		0010																																																																																																
Which molecular markers do you check in a patient with a newly diagnosed NSCLC?       13         Only EGFR mutation (according to the clinical data)       -         Only MDA.KL Kuison (according to the clinical data)       -         All of the above       13       75.         Other       13       75.         Other       13       76.         Out peeck molecular markers based on a priority ranking?       -       -         Yes       76       40.         No       110       58.       -         Based on readily available kit       21       11.         Immunohistochemistry<		100	52.9																																																																																																
Only EGFR mutation (according to the clinical data)         -         -           Only EML-ALK fusion (according to the clinical data)         -         -           All of the above         143         757           Other         21         100           Do you check molecular markers based on a priority ranking?         -           Yes         76         400           No         110         58           f"Yes":         -         -           Based on readily available kit         21         110           Based on readily available kit         21         111           Based on readily available kit         21         11           Immunohistochemistry         11         53.           Immunohistochemistry         30         15.           Inmunohistochemistry and subsequent FISH         30         14.           Mor do you check for molecular markers?	l do not check molecular tests	1	0.5																																																																																																
Only EGFR mutation (according to the clinical data)         -         -           Only EML-ALK fusion (according to the clinical data)         -         -           All of the above         143         757           Other         21         100           Do you check molecular markers based on a priority ranking?         -           Yes         76         400           No         110         58           f"Yes":         -         -           Based on readily available kit         21         110           Based on readily available kit         21         111           Based on readily available kit         21         11           Immunohistochemistry         11         53.           Immunohistochemistry         30         15.           Inmunohistochemistry and subsequent FISH         30         14.           Mor do you check for molecular markers?	Which molecular markers do you check in a patient with a newly diagnosed NSCLC?																																																																																																		
Only EML-ALK fusion (according to the clinical data)       -       -         Only ROS-1 mutation (according to the clinical data)       -       -         All of the above       143       75.         Other       21       10.         Do you check molecular markers based on a priority ranking?       -       -         Yes       76       40.         No       110       58.         67''Es''.       50       26.         Based on reimbursement       50       26.         Based on readily available kit       21       11.         Based on the functal status of the patient       30       17.         Which method is used for ALK mutation?       11       53.         Immunohistochemistry       11       53.         Immunohistochemistry and subsequent FISH       30       15.         In all NSCLEs even non-metastatic patients       34       22.         Att erexcond line in metastatic patients		25	13.2																																																																																																
All of the above       143       75.         Other       0.       21       10.         Do you check molecular markers based on a priority ranking?       76       40.         No       10       58.         Yes       76       40.         No       10       58.         Firses:       21       11.         Based on reimbursement       50       26.         Based on readily available kit       21       11.         Based on the clinical status of the patient       33       31.         Mink method is used for ALK mutation?       11       53.         Immunohistochemistry       11       54.         Inmunohistochemistry and subsequent FISH       30       15.         When do you check for molecular markers?       142       75.         At second line in metastatic patients       34       14.         After metastasis in metastatic patients       34       14.         After metastasis in metastatic patients       38       20.         Myself       167       88.         My colleague (medical oncologist)       43       22.         Mher do you receive the results of molecular marker tests?       18       9.         1-7 days		-	-																																																																																																
Other         21         10.           Do you check molecular markers based on a priority ranking?         76         40.           No         110         58.           No         110         58.           Based on rembursement         50         26.           Based on readily available kit         21         11.           Based on redily available kit         21         11.           Based on the clinical status of the patient         33         17.           Mich method is used for ALK mutation?         11         55.           Immunohistochemistry         11         55.           Men do you check for molecular markers?         12         75.           At diagnosis of locally advanced or metastatic patients         38         20.           Mhen do you checking molecular or genetic mutations?         15.         16.	Only ROS-1 mutation (according to the clinical data)	-	-																																																																																																
Do you check molecular markers based on a priority ranking?         76         40.           Yes         76         40.           No         10         58.           f"Yes".         88.         76.         40.           Based on reimbursement         50         26.           Based on readily available kit         21         11.           Based on the clinical status of the patient         33         17.           Which method is used for ALK mutation?         11         53.           Immunohistochemistry         11         53.           Immunohistochemistry and subsequent FISH         30         15.           Mhen do you check for molecular markers?         17         9           At diagnosis of locally advanced or metastatic patients         31.         14.           After metastasis in metastatic patients         32.         14.           After metastasis in metastatic patients         32.         14.           Myself         167         88.         20.           Mon makes requests for checking molecular marker tests?         18         92.           1-7 days         32         31.         32.           Mon olay urceive the results of molecular marker tests?         33         32.		143	75.7																																																																																																
Yes         76         40,           No         110         58.           No         100         58.           Based on readily available kit         21         111.           Based on readily available kit         21         111.           Based on the clinical status of the patient         33         177.           Which method is used for ALK mutation?         111         54.           Immunohistochemistry         111         54.           Immunohistochemistry and subsequent FISH         30         15.           Mhen do you check for molecular markers?         111         54.           In all NSCLCs even non-metastatic         17         9           At diagnosis of locally advanced or metastatic patients         38         20.           Mben do you check for checking molecular or genetic mutations?         38         20.           Myself         167         88.         44.           Myself         167         88.         45.           More than 21 days         59         31.         44.           15-21 days         59         31.         44.           More than 21 days         59         31.         44.           Lontinue with chemotherapy?         12	Other	21	10.5																																																																																																
No         110         58.           Based on reimbursement         50         26.           Based on readily available kit         21         11.           Mich method is used for ALK mutation?         11         5.4.           Immunohistochemistry         11         5.4.           Indi NSCLCs even non-metastatic         17         9           At diagnosis of locally advanced or metastatic patients         3         1.4.           After metastasis in metastatic patients         3         2.0.           Who makes requests for checking molecular marker tests?         167         88.           My colleague (medical oncologist)         43         2.2.           When do you receive the results of molecular marker tests?         11         1.4.           1-7 days         18         9.4.         9.3.         3.0.         3.0.           My colleague (medical oncologist)         43         2.2.         When do you receive the results of molecular marker tests?         21         11. </td <td>Do you check molecular markers based on a priority ranking?</td> <td></td> <td></td>	Do you check molecular markers based on a priority ranking?																																																																																																		
ff"Yes": Based on reimbursement Based on reim	Yes	76	40.2																																																																																																
Based on reimbursement5026.Based on readily available kit2111.Based on readily available kit3317.Which method is used for ALK mutation?3174.FISH14174.Immunohistochemistry115.3.Immunohistochemistry and subsequent FISH3015.When do you check for molecular markers?14275.In all NSCLCs even non-metastatic patients3114.After metastasis in metastatic patients38200.Myself16788.34.Myself undoju check for molecular marker tests?16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.31.S-14 days189.31.1-7 days2312.11.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy2312.12.12.I continue with chemotherapy of colleague of chemotherapy at diagnosis, and reported to be EGFR or3920.I diedie according to assessment after 2 or 3 cycles of chemo12968.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?12768.36.No12968.36.36.36.36.36.Do you give maintenance to patients that respond to chemotherapy r	No	110	58.2																																																																																																
Based on readily available kit2111.Based on the clinical status of the patient3317.Which method is used for ALK mutation?3174.Immunohistochemistry1174.Immunohistochemistry and subsequent FISH3015.When do you check for molecular markers?179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients314.After metastasis in metastatic patients314.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.11.Mat days2931.11.More than 21 days189.9.1.5.21 days3931.31.More than 21 days2331.31.More than 21 days2331.31.More than 21 days3332.31.More than 21 days3332.31.More than 21 days3332.33.I cease chemotherapy at shift to targeted therapy3332.I cease chemotherapy at shift to targeted therapy33.32.I cease chemotherapy at shift to targeted therapy33.32.I cease chemotherapy at shift to targeted therapy33.32.I cease chemotherapy at shift to targeted therapy without checking for mutation status, what is the choice37.	If "Yes":																																																																																																		
Based on the clinical status of the patient3317.Which method is used for ALK mutation?1174.FISH1174.Immunohistochemistry115.1Immunohistochemistry and subsequent FISH3015.When do you check for molecular markers?179In all NSCLGs even non-metastatic179At diagnosis of locally advanced or metastatic patients31.4At remetastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?31.4My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.91-7 days189.931.More than 21 days2111.11.Mata is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I cease chemotherapy and shift to targeted therapy2312.29.68.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?17.61.Yes6836.37.32.32.I cease chemotherapy and shift to targeted therapy23.12.68.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?17.61.Yes6836.36.37.37.37.I consider initiating targeted therapy without checking for mutation status, what is the choice of cyuotoxic chemotherapy reg		50	26.5																																																																																																
Which method is used for ALK mutation?         FISH       141       74.         Immunohistochemistry       11       5.3.         Inmunohistochemistry and subsequent FISH       30       15.         When do you check for molecular markers?       17       9         In all NSCLCs even non-metastatic       17       9         At diagnosis of locally advanced or metastatic patients       3       1.4.         After metastasis in metastatic patients       3       2.0.         Who makes requests for checking molecular or genetic mutations?       8       20.         When do you receive the results of molecular marker tests?       8       42.         1-7 days       18       9.2.         8-14 days       5       45       45         15-21 days       59       31.       31.         More than 21 days       18       9.2.       32.         8-14 days       5       45       45         15-21 days       59       31.       31.         More than 21 days       39       20.       11.         I continue with chemotherapy?       21       11.       11.         I continue with chemotherapy       39       20.       20.       23       20.			11.1																																																																																																
FISH       141       74.         Immunohistochemistry       11       5.4         Immunohistochemistry and subsequent FISH       30       15.5         When do you check for molecular markers?       17       9         At diagnosis of locally advanced or metastatic patients       142       75.         At second line in metastatic patients       38       20.         Who makes requests for checking molecular or genetic mutations?       3       1.4         My colleague (medical oncologist)       43       22.         When do you receive the results of molecular marker tests?       167       88.         My colleague (medical oncologist)       43       92.         1-7 days       18       9.1         8-14 days       59       31.         15-21 days       59       31.         More than 21 days       59       31.         More than 21 days       59       31.         I continue with chemotherapy?       21       11.         I continue with chemotherapy       39       20.         I decide according to assessment after 2 or 3 cycles of chemo       29       68.         Oo you give maintenance to patients that respond to chemotherapy regardless of the mutation status?       50.       50.		33	17.4																																																																																																
Immunohistochemistry115.4Immunohistochemistry and subsequent FISH3015.When do you check for molecular markers?79In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.4After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?31.6My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.21-7 days189.331.More than 21 days5931.31.More than 21 days2111.11.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy?2321.11.I case chemotherapy and shift to targeted therapy3920.20.I decide according to assessment after 2 or 3 cycles of chemo12968.Oo you give maintenance to patients that respond to chemotherapy regardless of the mutation status?37.37.Yes6836.36.36.No17.61.75.61.75.Yes6836.36.36.36.No31.32.37.37.37.Yes6836.36.36.36.No31.37.37.37. <td></td> <td></td> <td></td>																																																																																																			
Immunohistochemistry and subsequent FISH3015.When do you check for molecular markers?179In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?3820.Wyself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.51-7 days189.5458-14 days5931.31.More than 21 days5931.31.More than 21 days2321.11.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2320.I cease chemotherapy and shift to targeted therapy?2320.20.I decide according to assessment after 2 or 3 cycles of chemo2968.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status, what is the choice36.36.On on the chemotherapy regimen at first line in metastatic lung adenocancers?36.36.36.On on the approprime at first line in metastatic lung adenocancers?37.37.37.On the on therapy regimen at first line in metastatic lung adenocancers?37.37.37.On the one on the chemotherapy on the one o			74.6																																																																																																
When do you check for molecular markers?179In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.0After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?1743.1-7 days189.8-14 days5931.8-14 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy2312.12.I cease chemotherapy and shift to targeted therapy3920.20.I decide according to assessment after 2 or 3 cycles of chemo2312.Ov you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.No1761.61.61.No1761.61.61.61.No1761.61.61.61.No1761.61.61.61.No1761.61.61.61.No1761.61.61.61.No1761.61.61.61. <tr <tr="">No1761.<td></td><td></td><td>5.8</td></tr> <tr><td>In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.4After metastasis in metastatic patients320.Who makes requests for checking molecular or genetic mutations?16788.Myself16788.4322.When do you receive the results of molecular marker tests?189.11-7 days189.19.18-14 days5931.More than 21 days5931.Mat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or1211.ALK-positive after initiation of the chemotherapy?2312.12.I cease chemotherapy and shift to targeted therapy3920.20.20.I decide according to assessment after 2 or 3 cycles of chemo12968.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.Yes6836.30.30.30.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.61.No17</td><td></td><td>30</td><td>15.9</td></tr> <tr><td>At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.0After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?3820.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.11-7 days189.18-14 days5931.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy2312.12.I continue with chemotherapy3920.20.I decide according to assessment after 2 or 3 cycles of chemo2968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636.36.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice6836.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.</td><td></td><td>17</td><td>0</td></tr> <tr><td>At second line in metastatic patients31.6After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?320.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days189.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy2968.36.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?68.36.36.Yes68.36.31.117.61.f you consider initiating targeted therapy without checking for mutation status, what is the choice117.61.of cytotxic chemotherapy regimen at first line in metastatic lung adenocancers?59.31.</td><td></td><td></td><td></td></tr> <tr><td>After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?88Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?89.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.Mhat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy3920.20.2312.I decide according to assessment after 2 or 3 cycles of chemo12968.36.36.No1761.61.61.61.61.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.</td><td></td><td></td><td></td></tr> <tr><td>Who makes requests for checking molecular or genetic mutations?16788.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days5931.More than 21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I case chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.</td><td></td><td></td><td></td></tr> <tr><td>Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.</td><td></td><td>50</td><td>20.1</td></tr> <tr><td>My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?1761.Yes68361061.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?1761.</td><td></td><td>167</td><td>88.4</td></tr> <tr><td>When do you receive the results of molecular marker tests?189.41-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.</td><td>· ·</td><td></td><td>22.8</td></tr> <tr><td>1-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931.</td><td></td><td>15</td><td>22.0</td></tr> <tr><td>8-14 days854515-21 days5931More than 21 days2111What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111ALK-positive after initiation of the chemotherapy?2312I continue with chemotherapy and shift to targeted therapy2320I decide according to assessment after 2 or 3 cycles of chemo12968Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836No11761If you consider initiating targeted therapy without checking for mutation status, what is the choice11761of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931</td><td></td><td>18</td><td>9.5</td></tr> <tr><td>15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2320.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.11761.No11761.65.65.65.of you consider initiating targeted therapy without checking for mutation status, what is the choice56.56.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.57.</td><td></td><td></td><td>45</td></tr> <tr><td>More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.</td><td></td><td></td><td>31.2</td></tr> <tr><td>What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR orALK-positive after initiation of the chemotherapy?I continue with chemotherapyI continue with chemotherapyI cease chemotherapy and shift to targeted therapyI decide according to assessment after 2 or 3 cycles of chemoDo you give maintenance to patients that respond to chemotherapy regardless of the mutation status?YesNo10If you consider initiating targeted therapy without checking for mutation status, what is the choiceof cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td>·</td><td></td><td>11.1</td></tr> <tr><td>ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683611761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?565656</td><td>•</td><td></td><td></td></tr> <tr><td>I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050</td><td>ALK-positive after initiation of the chemotherapy?</td><td></td><td></td></tr> <tr><td>I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050</td><td></td><td>23</td><td>12.2</td></tr> <tr><td>Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td></td><td>39</td><td>20.6</td></tr> <tr><td>Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td>I decide according to assessment after 2 or 3 cycles of chemo</td><td>129</td><td>68.3</td></tr> <tr><td>No       117       61.         If you consider initiating targeted therapy without checking for mutation status, what is the choice       61.         of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?       61.</td><td>Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?</td><td></td><td></td></tr> <tr><td>f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td>Yes</td><td>68</td><td>36</td></tr> <tr><td>of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td>No</td><td>117</td><td>61.9</td></tr> <tr><td></td><td>If you consider initiating targeted therapy without checking for mutation status, what is the choice</td><td></td><td></td></tr> <tr><td>Cisplatin + Pemetrexed 95 50.</td><td>of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?</td><td></td><td></td></tr> <tr><td></td><td>Cisplatin + Pemetrexed</td><td>95</td><td>50.2</td></tr>			5.8	In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.4After metastasis in metastatic patients320.Who makes requests for checking molecular or genetic mutations?16788.Myself16788.4322.When do you receive the results of molecular marker tests?189.11-7 days189.19.18-14 days5931.More than 21 days5931.Mat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or1211.ALK-positive after initiation of the chemotherapy?2312.12.I cease chemotherapy and shift to targeted therapy3920.20.20.I decide according to assessment after 2 or 3 cycles of chemo12968.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.Yes6836.30.30.30.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.61.No17		30	15.9	At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.0After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?3820.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.11-7 days189.18-14 days5931.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy2312.12.I continue with chemotherapy3920.20.I decide according to assessment after 2 or 3 cycles of chemo2968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636.36.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice6836.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.		17	0	At second line in metastatic patients31.6After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?320.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days189.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy2968.36.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?68.36.36.Yes68.36.31.117.61.f you consider initiating targeted therapy without checking for mutation status, what is the choice117.61.of cytotxic chemotherapy regimen at first line in metastatic lung adenocancers?59.31.				After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?88Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?89.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.Mhat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy3920.20.2312.I decide according to assessment after 2 or 3 cycles of chemo12968.36.36.No1761.61.61.61.61.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.				Who makes requests for checking molecular or genetic mutations?16788.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days5931.More than 21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I case chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.				Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.		50	20.1	My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?1761.Yes68361061.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?1761.		167	88.4	When do you receive the results of molecular marker tests?189.41-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.	· ·		22.8	1-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931.		15	22.0	8-14 days854515-21 days5931More than 21 days2111What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111ALK-positive after initiation of the chemotherapy?2312I continue with chemotherapy and shift to targeted therapy2320I decide according to assessment after 2 or 3 cycles of chemo12968Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836No11761If you consider initiating targeted therapy without checking for mutation status, what is the choice11761of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931		18	9.5	15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2320.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.11761.No11761.65.65.65.of you consider initiating targeted therapy without checking for mutation status, what is the choice56.56.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.57.			45	More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.			31.2	What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR orALK-positive after initiation of the chemotherapy?I continue with chemotherapyI continue with chemotherapyI cease chemotherapy and shift to targeted therapyI decide according to assessment after 2 or 3 cycles of chemoDo you give maintenance to patients that respond to chemotherapy regardless of the mutation status?YesNo10If you consider initiating targeted therapy without checking for mutation status, what is the choiceof cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	·		11.1	ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683611761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?565656	•			I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050	ALK-positive after initiation of the chemotherapy?			I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050		23	12.2	Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?		39	20.6	Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	I decide according to assessment after 2 or 3 cycles of chemo	129	68.3	No       117       61.         If you consider initiating targeted therapy without checking for mutation status, what is the choice       61.         of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?       61.	Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?			f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	Yes	68	36	of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	No	117	61.9		If you consider initiating targeted therapy without checking for mutation status, what is the choice			Cisplatin + Pemetrexed 95 50.	of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?				Cisplatin + Pemetrexed	95	50.2
		5.8																																																																																																	
In all NSCLCs even non-metastatic179At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.4After metastasis in metastatic patients320.Who makes requests for checking molecular or genetic mutations?16788.Myself16788.4322.When do you receive the results of molecular marker tests?189.11-7 days189.19.18-14 days5931.More than 21 days5931.Mat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or1211.ALK-positive after initiation of the chemotherapy?2312.12.I cease chemotherapy and shift to targeted therapy3920.20.20.I decide according to assessment after 2 or 3 cycles of chemo12968.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.Yes6836.30.30.30.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.No1761.61.61.61.61.61.No17		30	15.9																																																																																																
At diagnosis of locally advanced or metastatic patients14275.At second line in metastatic patients31.0After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?3820.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.11-7 days189.18-14 days5931.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.I continue with chemotherapy2312.12.I continue with chemotherapy3920.20.I decide according to assessment after 2 or 3 cycles of chemo2968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636.36.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice6836.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.		17	0																																																																																																
At second line in metastatic patients31.6After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?320.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days189.15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy2968.36.36.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?68.36.36.Yes68.36.31.117.61.f you consider initiating targeted therapy without checking for mutation status, what is the choice117.61.of cytotxic chemotherapy regimen at first line in metastatic lung adenocancers?59.31.																																																																																																			
After metastasis in metastatic patients3820.Who makes requests for checking molecular or genetic mutations?88Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?89.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.Mhat is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.12.I continue with chemotherapy3920.20.2312.I decide according to assessment after 2 or 3 cycles of chemo12968.36.36.No1761.61.61.61.61.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.																																																																																																			
Who makes requests for checking molecular or genetic mutations?16788.Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days5931.More than 21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I case chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.																																																																																																			
Myself16788.My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes683636No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.		50	20.1																																																																																																
My colleague (medical oncologist)4322.When do you receive the results of molecular marker tests?189.1-7 days189.8-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or12ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?1761.Yes68361061.No1761.61.61.If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?1761.		167	88.4																																																																																																
When do you receive the results of molecular marker tests?189.41-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.	· ·		22.8																																																																																																
1-7 days189.48-14 days854515-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836.No11761.f you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931.		15	22.0																																																																																																
8-14 days854515-21 days5931More than 21 days2111What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2111ALK-positive after initiation of the chemotherapy?2312I continue with chemotherapy and shift to targeted therapy2320I decide according to assessment after 2 or 3 cycles of chemo12968Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836No11761If you consider initiating targeted therapy without checking for mutation status, what is the choice11761of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?5931		18	9.5																																																																																																
15-21 days5931.More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2320.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.11761.No11761.65.65.65.of you consider initiating targeted therapy without checking for mutation status, what is the choice56.56.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?57.57.57.			45																																																																																																
More than 21 days2111.What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR or2312.ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?11761.Yes6836.No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?11761.			31.2																																																																																																
What is your approach to a patient who took chemotherapy at diagnosis, and reported to be EGFR orALK-positive after initiation of the chemotherapy?I continue with chemotherapyI continue with chemotherapyI cease chemotherapy and shift to targeted therapyI decide according to assessment after 2 or 3 cycles of chemoDo you give maintenance to patients that respond to chemotherapy regardless of the mutation status?YesNo10If you consider initiating targeted therapy without checking for mutation status, what is the choiceof cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	·		11.1																																																																																																
ALK-positive after initiation of the chemotherapy?2312.I continue with chemotherapy2312.I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683611761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?565656	•																																																																																																		
I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050	ALK-positive after initiation of the chemotherapy?																																																																																																		
I cease chemotherapy and shift to targeted therapy3920.I decide according to assessment after 2 or 3 cycles of chemo12968.Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?6836Yes683636No11761.If you consider initiating targeted therapy without checking for mutation status, what is the choice11761.of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?505050		23	12.2																																																																																																
Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?		39	20.6																																																																																																
Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status? Yes 68 36 No 117 61. If you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	I decide according to assessment after 2 or 3 cycles of chemo	129	68.3																																																																																																
No       117       61.         If you consider initiating targeted therapy without checking for mutation status, what is the choice       61.         of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?       61.	Do you give maintenance to patients that respond to chemotherapy regardless of the mutation status?																																																																																																		
f you consider initiating targeted therapy without checking for mutation status, what is the choice of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	Yes	68	36																																																																																																
of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?	No	117	61.9																																																																																																
	If you consider initiating targeted therapy without checking for mutation status, what is the choice																																																																																																		
Cisplatin + Pemetrexed 95 50.	of cytotoxic chemotherapy regimen at first line in metastatic lung adenocancers?																																																																																																		
	Cisplatin + Pemetrexed	95	50.2																																																																																																

#### Table 2. CONT.

How are mutation analyses reimbursed?		
SGK (social security institution)	155	82
Patient self-sponsored	14	7.4
SGK and patient share	16	8.5
Being included in compassionate use	11	5.8
What is the primary site for mutation analyses?		
Primary lung tumor mass	181	95.8
Mediastinal LAP	31	16.4
Metastasis site	19	10.1
If there is no adequate biopsy material for molecular study, do you recommend re-biopsy?		
Yes	173	91.5
No	14	7.4
Do you request a second biopsy in cases of EGFR/ALK discordance?		
Yes	72	38.1
No	112	59.3
For which cases do you request a second biopsy?		
For every patient that progressed during treatment	87	46
For patients that test negative but clinically positive based on my consideration	88	46.6
For young patients	42	22.2
For patients who have not smoked before	47	34.9

mining factor for choosing analyses. This is also known as a significant factor on this topic in the literature. Several previous studies have reported that non-reimbursement of these methods, particularly next generation sequencing techniques, should be a major barrier for widespread application of these procedures in clinical practice.<sup>[19]</sup> A previous report also stated that, even if the costs of these tests decrease to an affordable level for patients themselves, there should still be avoidance for those self-sponsored analyses in an environment where many other costs are covered by social security institutions.<sup>[20]</sup> From this point of view, developing a national strategy and health policy for covering and promotion of application of genetic and molecular studies should be a proper approach to both increase the quality of patient management and improve the patient outcomes by means of both survival and quality of life. In this study, we found that the social security institution of Turkey reimbursed more than 80% of the molecular analyses requested. This is an important measure for promoting widespread adoption of these tests among medical oncologists in Turkey.

In this study, we found that molecular and genetic testing is widely adopted and used in most occasions by medical oncologists in Turkey. Nevertheless, the limited availability of these tests at every center and the wait times for the results cause oncologists to initiate treatment based on clinical findings. If these methods become more available, the society will embrace their utilization in clinical practice.

#### Disclosures

**Ethics Committee Approval:** This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained from the Clinical Research Ethics Committee of Suleyman Demirel University, Faculty of Medicine, for this study (Date: 12/21/2020, Decision no: 395).

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Authorship Contributions: Concept – H.I.P.; Design–H.I.P.; Supervision – H.I.P.; Materials – H.I.P., V.A.A.; Data collection &/or processing – H.I.P., V.A.A.; Analysis and/or interpretation – H.I.P., V.A.A.; Literature search – H.I.P., V.A.A.; Writing – H.I.P., V.A.A.; Critical review – H.I.P., V.A.A.

#### References

- Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Threat 2012;134:333-43.
- Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92. [CrossRef]
- 3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74. [CrossRef]
- 4. Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpre-

- 5. Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov 2013;3:27-34. [CrossRef]
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E86. [CrossRef]
- Sung MR, Ellis PM, Verma S, Duncan E, Leighl NB. Approach to biomarker testing: perspectives from various specialties. Curr Oncol 2016;23:178-83. [CrossRef]
- Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38.
- Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8. [CrossRef]
- Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. [CrossRef]
- 11. Jänne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013;14:38-47. [CrossRef]
- 12. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non–small-cell lung cancer. J Clin Oncol 2013;31:4105-14.
- 13. Shaw AT, Ou S-HI, Bang Y-J, Camidge DR, Solomon BJ, Salgia R,

et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71. [CrossRef]

- Juan O, Popat S. Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications. Ther Adv Med Oncol 2017;9:201-16. [CrossRef]
- Ghafoor Q, Baijal S, Taniere P, O'Sullivan B, Evans M, Middleton G. Epidermal Growth Factor Receptor (EGFR) kinase inhibitors and Non-Small Cell Lung Cancer (NSCLC) – advances in molecular diagnostic techniques to facilitate targeted therapy. Pathol Oncol Res 2017;24:723–31. [CrossRef]
- 16. Joosten SEP, Retèl VP, Coupé VMH, van den Heuvel MM, van Harten WH. Scenario drafting for early technology assessment of next generation sequencing in clinical oncology. BMC Cancer 2016;16:66. [CrossRef]
- Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN. Multi-marker solid tumor panels using next-generation sequencing to direct molecularly targeted therapies. PLoS Curr 2014;6:ecurrents.eogt.aa5415d435fc886145bd7137a280a971. [CrossRef]
- 18. Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, et al. Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. Trials 2016;17:17. [CrossRef]
- Trosman JR, Weldon CB, Kelley RK, Phillips KA. Challenges of coverage policy development for next-generation tumor sequencing panels: Experts and payers weigh in. J Natl Compr Canc Netw 2015;13:311-8. [CrossRef]
- 20. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precision medicine for metastatic breast cancer—limitations and solutions. Nat Rev Clin Oncol 2015;12:693-704. [CrossRef]